See also: New and Experimental HIV Drugs and Treatments

General Information

• Ritonavir (Norvir) (AIDS InfoNet) and Spanish version
• Norvir (Poz)
• Combination Medications (AIDS InfoNet) and Spanish version
• Tybost (Poz)
• Cobicistat (COBI) (Test Positive Aware Network)

Selected Recent Articles

• Of Meds, ‘Boosters’ Most Likely to Clash With Recreational Drugs.  (September 2015, Poz)
• HIV-treatment ‘booster drugs’ are most likely to have dangerous interactions with methamphetamine, mephedrone, MDMA and ketamine.  (August 2015, AIDSmap)
• Cobicistat Safe for HIV-Positive Patients with Mild to Moderate Renal Impairment.  (October 2014, TheBody)
• Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP.  (September/October 2014, HIV Treatment Bulletin)
• New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless . . .  (September 2014, Journal Watch)
• Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved as Individual HIV Drugs.  (September 2014, TheBody)
• HIV/AIDS Update: Approval of Tybost (cobicistat) 150 mg tablets.  (September 2014, U.S. Food and Drug Administration)
• FDA Approves HIV Treatment Boosting Agent Tybost (Cobicistat)  (September 2014, Poz)
• BMS Files for FDA Approval of Reyataz/Cobicistat Combo Pill.  (April 2014, Poz)